- Home
- KRMD vs CHRS Comparison
KRMD vs CHRS Comparison
Compare KRMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- CHRS
- Stock Information
- Founded
- KRMD 1980
- CHRS 2010
- Country
- KRMD United States
- CHRS United States
- Employees
- KRMD N/A
- CHRS N/A
- Industry
- KRMD Medical/Dental Instruments
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRMD Health Care
- CHRS Health Care
- Exchange
- KRMD Nasdaq
- CHRS Nasdaq
- Market Cap
- KRMD 187.5M
- CHRS 191.3M
- IPO Year
- KRMD N/A
- CHRS 2014
- Fundamental
- Price
- KRMD $4.09
- CHRS $1.31
- Analyst Decision
- KRMD Strong Buy
- CHRS Strong Buy
- Analyst Count
- KRMD 5
- CHRS 4
- Target Price
- KRMD $4.50
- CHRS $5.38
- AVG Volume (30 Days)
- KRMD 112.5K
- CHRS 1.9M
- Earning Date
- KRMD 03-12-2025
- CHRS 03-12-2025
- Dividend Yield
- KRMD N/A
- CHRS N/A
- EPS Growth
- KRMD N/A
- CHRS N/A
- EPS
- KRMD N/A
- CHRS N/A
- Revenue
- KRMD $31,993,796.00
- CHRS $304,340,000.00
- Revenue This Year
- KRMD $20.04
- CHRS $2.47
- Revenue Next Year
- KRMD $14.15
- CHRS N/A
- P/E Ratio
- KRMD N/A
- CHRS N/A
- Revenue Growth
- KRMD 11.57
- CHRS 44.19
- 52 Week Low
- KRMD $1.98
- CHRS $0.66
- 52 Week High
- KRMD $4.60
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- KRMD 57.22
- CHRS 41.36
- Support Level
- KRMD $3.81
- CHRS $1.38
- Resistance Level
- KRMD $4.30
- CHRS $1.60
- Average True Range (ATR)
- KRMD 0.19
- CHRS 0.13
- MACD
- KRMD -0.00
- CHRS -0.04
- Stochastic Oscillator
- KRMD 61.93
- CHRS 4.17
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.